TTrialPathMatch Me to Trials
โ† All states

Clinical Trials in Illinois

2,653 actively recruiting studies with sites in Illinois. Filter by condition or check your eligibility in under a minute.

Weight Loss & ObesityDiabetesDepression & AnxietyMigraine & HeadacheBack & Joint PainSleep Disorders
Recruiting

Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections

Gonorrhea ยท Chlamydia ยท Syphilis

The goal of this open-label, randomized trial is to assess the efficacy of doxycycline prophylaxis in reducing incidences of bacterial sexually transmitted infections (STIs) among adolescent and young adult females while also evaluating acceptability and antimicrobial resistance in order to inform public health policy.

Chicago, IL13โ€“29 yrsWomen
See details & check eligibility
Recruiting

Forceps vs. Snare IVC Filter Removal

DVT

IVC filters are mechanical filters placed in a patient's body to trap blood clots in the legs migrating to the lungs. When no longer indicated, interventional radiologists are consulted for IVC filter removal. Currently, many methods for extracting IVC filters exist. Two of the most common methods involve using an endovascular snare device or rigid forceps. We intend to prospectively compare these two methods in an attempt to see if one offers an advantage to the other. This will be compared by evaluating success rates and procedure time.

Chicago, IL18+ yrsAll genders
See details & check eligibility
Recruiting

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

Sickle Cell Anemia (HbSS, or HbSฮฒ-thalassemia0) ยท Albuminuria

Sickle cell anemia (SCA) is an inherited red blood disorder. The kidneys are among the most commonly affected organ systems in SCA. The Food and Drug Administration (FDA) has approved empagliflozin as a treatment to reduce the decline of kidney function in those with kidney disease. The proposed research study aims to determine whether empagliflozin can prevent the progression of kidney dysfunction in patients with sickle cell anemia (SCA) who are at high risk of developing advanced chronic kidney disease (CKD).

Chicago, IL18โ€“60 yrsAll genders
See details & check eligibility
Recruiting

Aromatherapy and Music Impact on Nurses' Stress at Work

Stress

The purpose of the Doctor of Nursing Practice research project is to determine if nurses who receive chamomile-lavender aromatherapy and listen to music during a 20-minute break once per shift for 8 weeks, will experience report decreased work stress (measured by self-reported symptoms of anxiety) compared to before the aromatherapy and music intervention during breaks. The investigators know nurses are at high risk for stress and anxiety. Despite the current processes and policies in place at Northwestern Memorial Hospital that support nurses to take breaks during their shifts, nurses continue to share feeling stressed and anxious. Included in this Doctor of Nursing Practice research project is an evidence synthesis of fourteen studies supporting the idea that combining aromatherapy and music can reduce anxiety in both adults and children. The evidence-based intervention being studied is administering lavender-chamomile essential oil aromatherapy and listening to music during 20-minute non-meal breaks once a shift for 8 weeks. Participants will go to a quiet breakroom, pour 3 drops of lavender-chamomile essential oil onto a non-adhesive 2X2 gauze pad, and place the pad about 20 centimeters from their noses while also listening to their preferred calming music through their personal phones and wireless earbuds or headphones for twenty minutes.

Chicago, IL18+ yrsAll genders
See details & check eligibility
Recruiting

Observational Study Protocol: LIVER-R

Hepatobiliary Cancers

Given the number of anticipated durvalumab-based treatment launches in the hepatobiliary cancer space over the next 3 years, there is a need to capture contemporary real-world data across these indications. LIVER-R is a multicountry, multicenter, observational study of patients with a confirmed diagnosis of hepatobiliary cancer treated with a durvalumab-based regimen as part of routine clinical practice or early access program (EAP). The study design will include primary and secondary data collection. The primary objective of this study is to evaluate the effectiveness of durvalumab-based regimens in real-world settings as measured by real-world overall survival. Other endpoints include demographics, clinical characteristics, clinically significant events of interest, treatment patterns, concomitant medications, and other real-world clinical endpoints (such as duration of treatment, progression-free survival, time to treatment progression, time to next treatment, recurrence-free survival, and time to treatment recurrence).

Evergreen Park, Hinsdale, IL18โ€“130 yrsAll genders
See details & check eligibility
Recruiting

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Carcinoma, Transitional Cell ยท Urinary Bladder Neoplasms ยท Neoplasm Metastasis

The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab. Study participation could last up to approximately 6 years.

Chicago, Evanston +more, IL18+ yrsAll genders
See details & check eligibility
Recruiting

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

Intracerebral Hemorrhage

The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 90 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy. FASTEST Part 2 is an extension of the FASTEST Trial where the subgroups include those treated within 2 hours with a positive spot sign on a baseline CT angiogram or patients treated within 90 minutes of stroke onset, with or without a positive spot sign.

Chicago, Winfield +more, IL18โ€“80 yrsAll genders
See details & check eligibility
Recruiting

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis

Colitis Ulcerative

This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe UC. The primary objective of this study is to assess efficacy of different doses of SAR441566 on clinical remission in participants with moderate-to-severe ulcerative colitis. This study will include a screening period of up to 28 days (+ 7 calendar days if needed) followed by the main study treatment period of 52 weeks which will be comprised of a double blind (DB) treatment period with 12 weeks of induction period followed by a maintenance period of 40 weeks and 2-week follow-up after end of treatment. Additionally, an Open Label (OL) period of up to 40 weeks will be offered to eligible participants (for participants not enrolling in the LTS study). * The study duration will be up to 59 weeks. * The treatment duration will be up to 52 weeks in the DB arm and up to 40 weeks in the OL arm. * The number of visits will be 12 for the main study treatment period and 8 for the OL treatment period.

Glenview, Gurnee, IL18โ€“75 yrsAll genders
See details & check eligibility
Recruiting

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naรฏve.

Metastatic Castration Sensitive Prostate Cancer (mCSPC) ยท Hormone Sensitive Prostate Cancer ยท Prostate Cancer

This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naรฏve and have not yet received chemotherapy in the mCSPC setting.

Chicago Ridge, Decatur +more, IL18+ yrsMen
See details & check eligibility
Recruiting

Wearable Sensors to Detect Atypical Muscle Activation in Young Infants

Neuromuscular Disorders ยท Motor Development ยท Muscle Tone

The purpose of this study is to see if wearable sensor technology can be used to evaluate muscle activity and/or identify atypical muscle tone in infants up to 48 weeks postmenstrual age (8 weeks corrected age). These sensors are placed on the surface of the skin and record data about a child's body movements and muscle activity.

Chicago, IL0โ€“0 yrsAll genders
See details & check eligibility
Recruiting

MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)

Prostate Cancer

The overarching goal is to prospectively recruit men considering active surveillance for treatment in the MAGIC (MRI And GPS Informing Choices for prostate cancer treatment) Cohort to provide meaningful data on active surveillance in Blacks and in men served in safety net hospitals. Recent studies highlight significant promise for multi-parametric magnetic resonance imaging of the prostate (MRI) and Genomic Prostate Score assay (GPS) as tools to help risk stratify men on active surveillance to identify men likely to harbor undetected aggressive disease in their prostate. Given the risk data provided by these modalities and the low adherence with monitoring common in men served in public hospitals, both tools may improve safety via improved patient selection and patient adherence with monitoring. The downside is that excessive testing may lead to too many false positives and unnecessary treatment. Two hundred men with very low to intermediate risk prostate cancer were randomized into the 2-arm ENACT Clinical trial from 2016-2019 to study the impact of the GPS assay on treatment choice. Overall, 104 men received GPS assay and 96 controls did not receive the assay (a confirmatory test) right after being newly diagnosed with favorable risk prostate cancer. For Aim 1, 222 men will be recruited into the MRI And GPS Informing Choices for prostate cancer treatment (MAGIC) study and they will be given the GPS assay and multi-parametric MRI of the prostate to provide personalized risk data for having aggressive tumors in their prostate. Between the ENACT and MAGIC study, there will be 3 groups of men who will have received both GPS \& MRI, GPS alone, or neither test and can compare the impact of having 0,1 or 2 confirmatory tests on patient's adherence to active surveillance monitoring protocols over 18 months. The analyses will elucidate whether 1 or 2 tests are needed to improve adherence to monitoring. Monitoring is vital for detecting tumor progression early and avoiding cancer metastasis and death. In Aim 2, the MAGIC study cohort will be leveraged to determine the accuracy of the Genomic Prostate Score assay and the prostate imaging- reporting and data system (PIRADS) score from the MRI in predicting which tumors will progress in 18 months. Progression is defined as increased Gleason grade group (GG) or change in prostate digital rectal examination findings. This serves two purposes. It will allow doctors and patients to categorize the patient as safe or risky for active surveillance. Secondly, it will allow doctors to identify which men on active surveillance need to be followed with annual prostate biopsies and which men can have their biopsies deferred for 3-5 years to reduce the number of prostate biopsies and their morbidities. Lastly in Aim 3, the participants will rank the importance of these tests among a multitude of clinical, social, financial and interpersonal influences on their cancer treatment choice. By tallying the patient rankings, one can identify the most critical decision making factors that can be used to encourage increased selection of active surveillance.

Chicago, IL40โ€“76 yrsMen
See details & check eligibility
Recruiting

The Trans-Led Care Study

Substance Abuse ยท Substance Addiction ยท Substance Use Disorder (SUD)

This study is testing a new mutual-help group called "the TLC program" for transgender adults who use substances or are recently in recovery. The TLC Program is based on Acceptance and Commitment Therapy or "ACT" which is a type of mental health counseling that focuses on using mindfulness skills to connect a person to their values and improve their mental health. The TLC Program was developed by transgender and gender diverse community members, mental health providers, and researchers.

Chicago, IL18+ yrsAll genders
See details & check eligibility
Recruiting

The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias

Relapsed or Resistant Acute Leukaemias

The most common types of acute leukaemia are acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). AML is a heterogenous clonal disorder of haemopoietic progenitor cells and the most common and severe malignant leukemia in adults and is responsible for the highest mortality from leukemia. ALL is a neoplasm characterized by the growth of malignant lymphoblasts of the B or T lineage, leading to an inhibition of proliferation of the normal blood cell lineages. The primary objectives of this study are investigating the safety, tolerability, and the MTD of LBS-007. The secondary objectives are to assess the efficacy and to determine the pharmacokinetics (PK) of LBS-007. The exploratory objective is to study and correlate the changes in surrogate biomarkers in response to treatment.

Chicago, IL18โ€“120 yrsAll genders
See details & check eligibility